

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	Confirmatory Grant of Security Interest in United States Patents (Exclusively Licensed Patents)

CONVEYING PARTY DATA

Name	Execution Date
Endo Pharmaceuticals Inc.	11/30/2010

RECEIVING PARTY DATA

Name:	JPMorgan Chase Bank, N.A., as Administrative Agent
Street Address:	10 South Dearborn
City:	Chicago
State/Country:	ILLINOIS
Postal Code:	60603

PROPERTY NUMBERS Total: 78

Property Type	Number
Patent Number:	6326357
Patent Number:	6809081
Patent Number:	6794368
Patent Number:	6329347
Patent Number:	7125858
Patent Number:	6890911
Patent Number:	5185377
Patent Number:	6455066
Patent Number:	6746689
Patent Number:	5776952
Application Number:	11361954
Application Number:	11349537
Application Number:	11462216
Application Number:	10890703

CH \$3120.00 6326357

Application Number:	10890763
Application Number:	11349544
Application Number:	10718112
Application Number:	10567594
Application Number:	11348276
Application Number:	11471438
Application Number:	11348295
Application Number:	10890704
Patent Number:	RE37355
Application Number:	11133190
Application Number:	10803187
Patent Number:	7361690
Patent Number:	7168937
Application Number:	11774816
Application Number:	11334344
Application Number:	12118231
Application Number:	12140665
Application Number:	12140718
Application Number:	12140444
Application Number:	12140609
Application Number:	12140470
Application Number:	12140496
Patent Number:	5709869
Patent Number:	5411738
Patent Number:	5589180
Patent Number:	5601838
Application Number:	12515429
PCT Number:	US0901541
Application Number:	61155371
Patent Number:	6319913
Patent Number:	6579865
Patent Number:	7157097
Patent Number:	5500448
Patent Number:	5770559
Patent Number:	5981474

Patent Number:	6613358
Patent Number:	5861174
Patent Number:	6482435
Patent Number:	5962501
Patent Number:	5616603
Patent Number:	5827871
Patent Number:	5637611
Patent Number:	5618948
Patent Number:	5917054
Patent Number:	6359146
Patent Number:	5618947
Patent Number:	5464864
Patent Number:	4780476
Patent Number:	4855422
Application Number:	10798780
Patent Number:	5447729
Patent Number:	6692767
Patent Number:	5484608
Patent Number:	6793934
Patent Number:	5595004
Patent Number:	5897876
Patent Number:	6838093
Patent Number:	5494915
Patent Number:	5599936
Patent Number:	5536263
Patent Number:	5741510
Patent Number:	6096333
Patent Number:	6096334
Patent Number:	6361790

CORRESPONDENCE DATA

Fax Number: (214)981-3400

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 214-981-3483

Email: dclark@sidley.com

Correspondent Name: Dusan Clark, Esq.

Address Line 1: Sidley Austin LLP
Address Line 2: 717 N. Harwood St., Suite 3400
Address Line 4: Dallas, TEXAS 75201

ATTORNEY DOCKET NUMBER: 36084-36730

NAME OF SUBMITTER: Dusan Clark

Total Attachments: 9

source=Exclusively Lic Patents CGSI#page1.tif
source=Exclusively Lic Patents CGSI#page2.tif
source=Exclusively Lic Patents CGSI#page3.tif
source=Exclusively Lic Patents CGSI#page4.tif
source=Exclusively Lic Patents CGSI#page5.tif
source=Exclusively Lic Patents CGSI#page6.tif
source=Exclusively Lic Patents CGSI#page7.tif
source=Exclusively Lic Patents CGSI#page8.tif
source=Exclusively Lic Patents CGSI#page9.tif

**CONFIRMATORY GRANT OF SECURITY INTEREST
IN UNITED STATES PATENTS**

THIS CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS (as the same may be amended, restated, supplemented or otherwise modified from time to time, the "Confirmatory Grant") is made effective as of November 30, 2010 by and from ENDO PHARMACEUTICALS INC., a Delaware corporation (the "Grantor"), to and in favor of JPMORGAN CHASE BANK, N.A., for itself and as Administrative Agent for the Secured Parties (as defined in the Credit Agreement referenced below) (in such capacities, the "Grantee").

WHEREAS, Endo Pharmaceuticals Holdings Inc. (the "Borrower"), the Lenders and the Grantee have entered into a Credit Agreement dated as of November 30, 2010 (as may be amended, restated, supplemented or otherwise modified from time to time, the "Credit Agreement").

WHEREAS, the Grantor, along with certain other Subsidiaries of the Borrower, has guaranteed the repayment of the Secured Obligations pursuant to a Guaranty dated as of November 30, 2010 (as may be amended, restated, supplemented or otherwise modified from time to time, the "Guaranty").

WHEREAS, the Borrower, the Grantor and certain Subsidiaries of the Borrower have entered into a Pledge and Security Agreement dated as of November 30, 2010 (as may be amended, restated, supplemented or otherwise modified from time to time, the "Security Agreement").

WHEREAS, the Grantor is the exclusive licensee of the patents listed on Exhibit A attached hereto (the "Patents"), which Patents are pending or registered with the United States Patent and Trademark Office.

WHEREAS, this Confirmatory Grant has been executed in conjunction with the security interest granted under the Security Agreement to the Grantee for the benefit of the Secured Parties. In the event that any provisions of this Confirmatory Grant are deemed to conflict with the Security Agreement, the provisions of the Security Agreement shall govern.

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, it is hereby agreed that:

1) Definitions. All capitalized terms not defined herein shall have the respective meaning given to them in the Credit Agreement.

2) The Security Interest.


(a) This Confirmatory Grant is made to secure the satisfactory performance and payment of (i) all the Secured Obligations and (ii) all of the obligations and liabilities of the Subsidiary Guarantors under the Guaranty. Upon the payment in full of all Secured Obligations (other than Unliquidated Obligations), the Grantee shall promptly, upon such satisfaction, execute, acknowledge, and deliver to the Grantor all reasonably requested instruments in writing releasing the security interest in the Patents acquired under the Security Agreement and this Confirmatory Grant.

(b) The Grantor hereby pledges and grants to the Grantee, on behalf of and for the benefit of the Secured Parties, a security interest in all of the Grantor's right, title and interest in and to the patents and patent applications under and to the extent set forth in and permitted by the exclusive license to Grantor of such patents and patent applications.

3) Governing Law. **THIS CONFIRMATORY GRANT SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAW OF THE STATE OF NEW YORK.**

IN WITNESS WHEREOF, the Grantor has executed this Confirmatory Grant effective as of the date first written above.

ENDO PHARMACEUTICALS INC.

By: 
Name: Alan G. Levin
Title: Executive Vice President and Chief Financial Officer

Signature Page for
Grant of Security Interest in United States Patents

PATENT
REEL: 025456 FRAME: 0178

CONFIRMATORY GRANT OF SECURITY INTEREST
IN UNITED STATES PATENTS
Exhibit A - SCHEDULE OF LICENSED PATENTS

Exhibit A

PATENT
REEL: 025456 FRAME: 0179

Licensed Patents

Title	Country	App. No.	App. Date	Patent No.	Issued	Owner
Bacterial cell complex composition and method of use	United States	09/129,312	5-Aug-98	6,326,357	4-Dec-01	Bioniche Life Sciences Inc.
Chemotherapeutic composition and method	United States	09/857,332	17-Sep-01	6,809,081	26-Oct-04	Bioniche Life Sciences Inc.
Composition and method for inducing apoptosis in prostate cancer cells	United States	09/937,643	10-Jan-02	6,794,368	21-Sep-04	Bioniche Life Sciences Inc.
Composition and method for the treatment of bladder cancer	United States	09/12,313	5-Aug-98	6,329,347	11-Dec-01	Bioniche Life Sciences Inc.
Hyaluronic acid in the treatment of cancer	United States	10/168,327	29-Aug-02	7,125,858	24-Oct-06	Bioniche Life Sciences Inc.
Method for the treatment of inflammation	United States	09/857,333	17-Sep-01	6,890,911	10-May-05	Bioniche Life Sciences Inc.
Diphenyl compounds which inhibit arachidonic acid metabolism, and their use in pharmaceutical compositions	United States	07/754,788	4-Sep-91	5,185,377	9-Feb-93	Ciba Specialty Chemicals Corporation
Intradermal-penetration agents for topical local anesthetic administration	United States	09/523,652	10-Mar-00	6,455,066	24-Sep-02	Epicept, Inc.
Intradermal-Penetration Agents for Topical Local Anesthetic Administration	United States	10/201,901	25-Mar-02	6,746,689	6/8/2004	Epicept Corporation
Method and composition for topical therapy of back pain and muscle tension	United States	08/682,352	17-Jul-96	5,776,952	7-Jul-98	Epicept Corporation**
Phosphate salts of 6-dimethylaminomethyl-1-(3-methoxyphenyl)-1,3-dihydroxy-cyclohexane compounds	United States	11/361,954	27-Feb-06			Grünenthal GmbH
Abuse-proofed dosage form	United States	11/349,537	5-Aug-04			Grünenthal GmbH
Abuse-proofed dosage form	United States	11/462,216	3-Aug-06			Grünenthal GmbH
Process for the production of an abuse-proofed solid dosage form	United States	10/890,703	14-Jul-04			Grünenthal GmbH
Abuse-proofed oral dosage form	United States	10/890,763	14-Jul-04			Grünenthal GmbH
Abuse-proofed oral dosage form	United States	11/349,544	6-Feb-06			Grünenthal GmbH
Abuse-proofed dosage form	United States	10/718,112	20-Nov-03			Grünenthal GmbH
Dosage form that is safeguarded from abuse	United States	10/567,594	5-Aug-04			Grünenthal GmbH
Process for the production of an abuse-proofed dosage form	United States	11/348,276	6-Feb-06			Grünenthal GmbH
Process for the production of an abuse-proofed dosage form	United States	11/471,438	23-Dec-04			Grünenthal GmbH
Crush resistant delayed-release dosage forms	United States	11/348,295	6-Feb-06			Grünenthal GmbH
Process for production of an abuse-proofed solid dosage form	United States	10/890,704	14-Jul-04			Grünenthal GmbH

Licensed Patents

Title	Country	App. No.	App. Date	Patent No.	Issued	Owner
6-Dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients	United States	09/539,528	30-Mar-00	RE 37,355	4-Sep-01	Grünenthal GmbH
Combination of selected analgesics and COX-II inhibitors	United States	11/133,190	20-May-05			Grünenthal GmbH
Combination of selected opioids with muscarine antagonists for treating urinary incontinence	United States	10/803,187	18-Mar-04			Grünenthal GmbH
Compositions and methods for the treatment of urinary incontinence	United States	10/978,565	2-Nov-04	7,361,690	22-Apr-08	Grünenthal GmbH
Method for the enzymatic resolution of the racemates of aminomethyl-aryl-cyclohexanol derivatives	United States	10/203,031	4-Nov-02	7,168,937	30-Jan-07	Grünenthal GmbH
Method of Inhibiting Inflammatory pain	United States	11/774,816	9-Sep-07			Grünenthal GmbH
Pharmaceutical composition containing 5-dimethylaminomethyl-1-(3-(3-methoxyphenyl)-cyclohexane-1,3-diol with delayed active ingredient release	United States	11/334,344	19-Jan-06			Grünenthal GmbH
Use of Axomadol for Treatment of Arthrosis Pain	United States	12/118,231	9-May-08			Grünenthal GmbH
Abuse proof dosage form	United States	12/140,665	17-Jun-08			Grünenthal GmbH
Process for the production of an abuse-proofed dosage form	United States	12/140,718	17-Jun-08			Grünenthal GmbH
Process for the production of an abuse-proofed dosage form	United States	12/140,444	17-Jun-08			Grünenthal GmbH
Process for the production of an abuse-proofed dosage form	United States	12/140,609	17-Jun-08			Grünenthal GmbH
Abuse proof dosage form	United States	12/140,470	17-Jun-08			Grünenthal GmbH
Process for the production of an abuse-proofed dosage form	United States	12/140,496	17-Jun-08			Grünenthal GmbH
Method for treating nerve injury pain associated with shingles	United States	08/773,529	23-Dec-96	5,709,869	20-Jan-98	Hind Health Care, Inc.
Method for treating nerve injury pain associated with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine	United States	08/198,223	16-Feb-94	5,411,738	2-May-95	Hind Health Care, Inc.

Licensed Patents

Title	Country	App. No.	App. Date	Patent No.	Issued	Owner
Method for treating nerve injury pain associates with shingles (herpes-zoster and post-herpetic neuralgia) by topical application of lidocaine	United States	08/611,168	5-Mar-96	5,589,180	31-Dec-96	Hind Health Care, Inc.
Method for treating pain associated with herpes-zoster and post-herpetic neuralgia	United States	07/526,771	18-May-90	5,601,838	11-Feb-97	Hind Health Care, Inc.
Methods, compositions, and kits for treating pain and pruritis	United States	12/515,429	19-May-09			President and Fellows of Harvard College
Methods, compositions, and kits for treating pain and pruritis	PCT	PCT/US2009/001541	11-Mar-09			President and Fellows of Harvard College
Methods, compositions, and kits for treating surgical, wound, neuropathic, and inflammatory pain	United States	61/155,371	25-Feb-09			President and Fellows of Harvard College
Penetration enhancing and irritation reducing systems	United States	09/189,090	9-Nov-98	6,319,913	20-Nov-01	Strakan International Limited
Penetration enhancing and irritation reducing systems	United States	09/963,287	24-Sep-01	6,579,865	17-Jun-03	Strakan International Limited
Penetration enhancing and irritation reducing systems	United States	10/389,715	12-Mar-03	7,157,097	2-Jan-07	Strakan International Limited
Recurrent aphthous ulcer treatment method	United States	241,827	12-May-94	5,500,448	19-Mar-96	Chesebrough-Pond's USA Co., Division of Conopco, Inc.
Solubilization of pharmaceutical substances in an organic solvent and preparation of pharmaceutical powders using the same	United States	08/473,008	6-Jun-95	5,770,559	23-Jun-98	Regents of the University of Colorado
Solubilization of pharmaceutical substances in an organic solvent and preparation of pharmaceutical powders using the same	United States	09/098,791	17-Jun-98	5,981,474	9-Nov-99	Regents of the University of Colorado
Sustained-release composition including amorphous polymer	United States	09/877,330	7-Jun-01	6,613,358	2-Sep-03	Regents of the University of Colorado
Temperature sensitive gel for sustained delivery of protein drugs	United States	08/679,199	12-Jul-96	5,861,174	19-Jan-99	Regents of the University of Colorado
Temperature sensitive gel for sustained delivery of protein drugs	United States	09/232,288	15-Jan-99	6,482,435	19-Nov-02	Regents of the University of Colorado
Enantiomer of carbazole derivative as 5-HT1-like agonists	United States	08/770,926	23-Dec-96	5,962,501	5-Oct-99	Venalis Development Limited

Licensed Patents

Title	Country	App. No.	App. Date	Patent No.	Issued	Owner
Enantiomers of carbazole derivatives as 5-ht1-like agonists	United States	08/451,898	26-May-95	5,616,603	1-Apr-97	Venalis Development Limited
Medicaments 1,2,3,4-tetrahydrocarbazoles and 5-ht ₁ agonist use thereof	United States	08/442,720	17-May-95	5,827,871	27-Oct-98	Venalis Development Limited
Medicaments	United States	08/442,719	15-May-95	5,637,611	10-Jun-97	Venalis Development Limited
Process for preparing an enantiomer of carbazole derivative	United States	08/451,846	26-May-95	5,618,948	8-Apr-97	Venalis Development Limited
Process for preparing enantiomers of carbazole derivatives as 5-ht ₁ -like agonists	United States	08/781,990	6-Jan-97	5,917,054	29-Jun-99	Venalis Development Limited
Process for the production of R-(+)-6-carboxamido-3-N-methylamino-1,2,3,4-tetrahydrocarbazole	United States	09/689,661	13-Oct-00	6,359,146	19-Mar-02	Venalis Development Limited
Process of preparing enantiomers of carbazole derivatives	United States	08/446,655	16-Dec-93	5,618,947	8-Apr-97	Venalis Development Limited
Use of tetrahydrocarbazone derivatives as 5ht ₁ receptor agonists	United States	08/167,846	23-Dec-93	5,464,864	7-Nov-95	Venalis Development Limited
Azoniapironotropanol Esters as Asthma Therapeutics and Broncholytics	United States	06/945,773	23-Dec-86	4,780,476	25-Oct-88	Madaus AG
Processes for the Preparation of Azoniapironotropanol Esters	United States	06/945,488	23-Dec-86	4,855,422	8-Aug-89	Madaus AG
Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels	United States	10/798,780	12-Mar-04			Bayer-Schering (Schering AG)
Multilamellar Drug Delivery System	United States	08/224,340	4/7/1994	5447729	9/5/1995	Supernus Pharmaceuticals, Inc
Solid Solution Beadlet	United States	09/156,464	9/18/1998	6692767	2/7/2004	Supernus Pharmaceuticals, Inc
Sustained-Release Drug Delivery System	United States	08/218/757	3/28/1994	5,484,608	1/16/1996	Supernus Pharmaceuticals, Inc
Solid oral dosage form	United States	09/457,248	12/8/1999	6,793,934	9/21/2004	Supernus Pharmaceuticals, Inc
Emulsified Drug Delivery System	United States	08/424,521	8/28/1995	5,595,004	9/14/1999	Supernus Pharmaceuticals, Inc

Licensed Patents

Title	Country	App. No.	App. Date	Patent No.	Issued	Owner
Emulsified Drug Delivery System	United States	08/9879,994	6/20/1997	5,897,876	4/27/2009	Supernus Pharmaceuticals, Inc
System for the Osmotic Delivery of Pharmaceutically Active Agents	United States	09/872,173	6/1/2001	6838093	1/4/2005	Supernus Pharmaceuticals, Inc
New isoindolinone derivative, its preparation and the pharmaceutical compositions which contain it	United States	08/286294	8/5/1994	5494915	2/27/1996	Aventis Pharma S.A.
New isoindolinone derivative, its preparation and the pharmaceutical compositions which contain it	United States	08/476749	6/7/1995	5599936	2/4/1997	Aventis Pharma S.A.
Non-Occlusive Adhesive Patch for Applying Medication to the Skin	United States	08/291,982	30-Mar-94	5,536,263	16-Jul-96	LecTec Corporation
Adhesive patch for applying analgesic medication to the skin	United States	08/629,191	8-Apr-96	5,741,510	21-Apr-98	LecTec Corporation
Method of forming adhesive patch for applying medication to the skin	United States	08/947,089	8-Oct-97	6,096,333	1-Aug-00	LecTec Corporation
Method of forming adhesive patch for applying medication to the skin	United States	09/211,222	14-Dec-98	6,096,334	1-Aug-00	LecTec Corporation
Method of forming adhesive patch for applying medication to the skin	United States	09/629,783	31-Jul-00	6,361,790	26-Mar-02	LecTec Corporation